Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxytocin - Tonix Pharmaceuticals

Drug Profile

Oxytocin - Tonix Pharmaceuticals

Alternative Names: Intranasal potentiated oxytocin - Tonix Pharmaceuticals; Oxytocin intranasal - Tonix Pharmaceuticals; TI-001; TI-114; TNX-1900; TNX-2900

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trigemina
  • Developer Massachusetts General Hospital; Tonix Pharmaceuticals Holding Corp; Trigemina
  • Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
  • Mechanism of Action Calcitonin gene-related peptide antagonists; Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Prader-Willi syndrome

Highest Development Phases

  • Phase II Binge-eating disorder; Migraine; Obesity; Pervasive child development disorders; Social phobia
  • Phase I Prader-Willi syndrome
  • Preclinical Pain
  • Research Diabetes mellitus; Glucose intolerance; Insulin resistance
  • No development reported Headache; Trigeminal neuralgia

Most Recent Events

  • 25 Mar 2024 The US FDA grants rare pediatric disease designation to intranasal oxytocin for the treatment of Prader-Willi syndrome in children and adolescents
  • 04 Dec 2023 Oxytocin is available for licensing as of 04 Dec 2023
  • 04 Dec 2023 US FDA approves IND application for oxytocin in Prader Willi syndrome
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top